To test this hypothesis, BE(2)C cells were treated with the CDK4/6 inhibitor Palbociclib (CDK4/6i) for 3 days, alone or in combination with ATRA to test whether the CDK4/6i might enhance the ATRA effects on neuroblastoma differentiation. This evidence concerns the gene CDK4 and neuroblastoma.